AI Article Synopsis
- Scientists are making great progress in treating liver and bile duct cancers using a method called immune checkpoint blockade (ICB), but it doesn't work well for everyone.
- Sometimes, even when the treatment starts to work, the cancer can become resistant, meaning it stops responding.
- Researchers are looking into why this happens and want to find new ways to make immunotherapy (a type of cancer treatment) work better for patients.
Article Abstract
Unprecedented advances have been achieved in hepatobiliary cancer treatment with immune checkpoint blockade (ICB). However, the efficacy of ICB in patients with hepatobiliary malignancies is still limited. Resistance to immunotherapies is often orchestrated by complicated tumor-host-microenvironment interactions but could also occur after initial efficacy, mostly when only partial responses are obtained. Clarification of cancer-resistance mechanisms will be beneficial to provide the rationale for the administration of personalized drugs. Here, we review the factors related to resistance to immune-targeted therapies in hepatobiliary malignancies and discuss the potential strategies for overcoming resistance and future directions of immunotherapy development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hbpd.2022.07.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!